Photophobia clinical trials

Explore recruiting photophobia clinical trials.

Recruiting photophobia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Photophobia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM).

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

C4951002 Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < 18 years of age

Sweden, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prestige 2- RimegePant in RElation to obeSiTy in miGainE

Austria

Phase III and phase IV (Integrated) EU CTIS Study details

Efficacy and safety assessment of T1695 ophthalmic suspension, versus Ciclosporin ophthalmic emulsion, in participants with moderate to severe Vernal Keratoconjunctivitis (VKC)

Spain, Italy, Bulgaria, France, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

Finland, Germany, Sweden, Austria, Belgium, France +4 more

Therapeutic use (Phase IV) EU CTIS Study details

Photophobia trials by city

Photophobia in Toronto Photophobia in Vancouver Photophobia in Montreal Photophobia in Calgary Photophobia in Edmonton Photophobia in Ottawa Photophobia in Winnipeg Photophobia in Quebec City Photophobia in Hamilton Photophobia in Kitchener Photophobia in London Photophobia in Halifax Photophobia in New York Photophobia in Los Angeles Photophobia in Chicago Photophobia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease